Ph 2 trial of Stenoparib with Temozolomide in Relapsed SCLC Open for Enrollment
“The opening of recruitment marks an important step in exploring stenoparib’s potential as a combination agent,” said Thomas Jensen, Chief Executive Officer of Allarity Therapeutics. “Based on clinical data to date from our ongoing trial in ovarian cancer, stenoparib has demonstrated a favorable safety profile, making it a strong candidate for combination therapies — particularly in settings where tolerability has been a limiting factor, as is the case in SCLC. More broadly, we believe stenoparib may offer meaningful clinical benefit in cancers where the WNT signaling pathway plays a key role, which applies to both SCLC and ovarian cancer. We’re particularly enthusiastic about taking this next step in stenoparib’s development as it allows us to explore stenoparib’s enormous potential in other indications and in combination with other agents.”
Share:
More News
“The initial efficacy data from the Part C studies are consistent with the encouraging efficacy signals we previously reported for Parts A and B of THIO-101, including an 88% disease control rate in third-line NSCLC patients. This measure of efficacy is close to triple the reported outcome for standard-of-care chemotherapy
“Patients with non-muscle invasive bladder cancer continue to face a significant risk of disease recurrence despite available treatment options,” said Mark Schoenberg, M.D., Chief Medical Officer of UroGen. “UGN-501 is an investigational next-generation oncolytic virus designed to selectively destroy tumor cells while generating an anti-tumor immune response. FDA clearance of
“Whitehawk has established strong expertise in ADC technology and oncology drug development,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “This collaboration further expands the application of Biocytogen’s fully human bispecific antibodies in ADC development. We look forward to supporting the efficient advancement of multiple programs by contributing high-quality
Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said: “The AZUR-1 results support the potential for dostarlimab to transform treatment for dMMR/MSI-H locally advanced rectal cancer. For many patients today, rectal cancer treatment comes with the tolerability burden and lasting impacts from chemotherapy, radiation and surgery. These data